AbCellera Biologics Inc. (ABCL) vs Definium Therapeutics, Inc. (DFTX)
A side-by-side comparison of AbCellera Biologics Inc. and Definium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABCL
AbCellera Biologics Inc.
$13.20HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
DFTX
Definium Therapeutics, Inc.
$34.80HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — ABCL vs DFTX
growth of $100 · dividends reinvested · last 6yABCL -76.6% (-21.5%/yr)DFTX -16.1% (-2.9%/yr)DFTX compounded faster over this window
ABCL DFTX
ABCL vs DFTX: by the numbers
- •DFTX is the larger company ($4.62B vs $4.03B market cap).
- •Both run net losses; DFTX's is the smaller (0.00% vs -248.83% net margin).
Metrics side by side
Valuation
| Metric | ABCL | DFTX |
|---|---|---|
| P/S ratio | 60.92 | N/A |
| P/B ratio | 4.50 | 5.03 |
Profitability
| Metric | ABCL | DFTX |
|---|---|---|
| Gross margin | 61.64% | 0.00% |
| Operating margin | -288.98% | 0.00% |
| Net margin | -248.83% | 0.00% |
| ROE | -18.38% | -38.51% |
| ROIC | -17.95% | -23.81% |
Growth (annualized)
| Metric | ABCL | DFTX |
|---|---|---|
| Revenue CAGR (5Y) | -31.78% | N/A |
| Total return CAGR (5Y) | -3.57% | 1.43% |
Frequently asked
- How have ABCL and DFTX total returns compared?
- Over the past 5 years, ABCL delivered -3.57% and DFTX delivered 1.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.